Jiangsu Bioda Life Science Co Ltd has launched the production of China's first homegrown vascular graft VASOLINE which helps connect blood vessels.

Du Guangwu, general manager of Bioda, said the Nantong-based company won the approval for marketing by the National Medical Products Administration on November 17, 2022. Du hailed VASOLINE as a result of the company's original research and development technology with better performance than foreign competitors.

China's increasing elderly population has led to the rising demand of vascular grafts. It's estimated that there are about 40,000-50,000 patients seeking surgery for diseased artery each year and most of them need vascular grafts to improve blood flow.